Kenvue (KVUE) 10-K Summary — Year Ended Dec 29, 2024
Kenvue Inc. filed its annual report for the period ended late 2024. The company reported revenue and operating cash flow that were essentially flat compared to the prior period, while operating income and net income showed improvement.
Key takeaway
Year ended Dec 29, 2024 · FY2025 10-K
Kenvue Inc. filed its annual report for the period ended late 2024. The company reported revenue and operating cash flow that were essentially flat compared to the prior period, while operating income and net income showed improvement.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$15.5B
Revenue reported for the fiscal year.
Operating income
$1.8B
Income from operations reported for the year.
Net income
$1B
Net income reported for the year.
Operating cash flow
$1.8B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jul 2, 2023 | $4B | n/a |
| Oct 1, 2023 | $3.9B | -2.4% |
| Dec 31, 2023 | $15.4B | +294.5% |
| Dec 29, 2024 | $15.5B | +0.1% |
Business overview
Kenvue is a consumer health company that markets a portfolio of brands in areas such as self-care, skin health, and essential health. The company focuses on brand marketing, product development, and innovation, supported by its supply chain and manufacturing operations. It competes in a regulated environment and emphasizes a healthy lives mission and governance practices.
Financial performance
Revenue remained nearly unchanged from the prior year, while operating cash flow was also stable. Operating income and net income both increased compared to the previous period, reflecting improved profitability.
Material risks
The company faces risks related to its reliance on top-tier banking partners for credit and cash management; a disruption could affect liquidity or increase capital costs. Additionally, historical financial data from its time as part of Johnson & Johnson may not reflect its standalone performance as an independent company. The filing also notes general regulatory and competitive risks inherent in the consumer health industry.
Liquidity and capital
The company relies on credit facilities and banking partners to support its liquidity and capital needs. A disruption to these partners could impact its ability to access credit or manage cash flows.
What to watch
Investors should monitor whether revenue growth resumes or continues to stagnate in the next filing.